Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| NovoCure Ltd | 416,474 | reported | 31 Dec 2025 | tx 197+4,769,336−6,299,046 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 31 Dec 2025 | GRANT_AWARD | NovoCure Ltd | 1 | 10.99 USD | |
| 30 Jun 2025 | GRANT_AWARD | NovoCure Ltd | 833 | 15.13 USD | |
| 01 Jan 2025 | GRANT_AWARD | NovoCure Ltd | 400,000 | 0.00 USD | |
| 31 Dec 2024 | GRANT_AWARD | NovoCure Ltd | 412 | 14.75 USD | |
| 28 Jun 2024 | GRANT_AWARD | NovoCure Ltd | 1,239 | 12.24 USD | |
| 30 Jun 2023 | GRANT_AWARD | NovoCure Ltd | 367 | 35.28 USD | |
| 06 Jan 2023 | GRANT_AWARD | NovoCure Ltd | 39 | 62.31 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 187,500 | 108.00 USD | |
| 05 Jan 2023 | EXERCISE | NovoCure Ltd | 187,500 | 7.15 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 999 | 117.01 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 1,344 | 119.35 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 500 | 119.99 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 1,395 | 116.06 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 3,702 | 115.21 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 4,568 | 114.35 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 2,000 | 112.86 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 8,369 | 111.23 USD | |
| 05 Jan 2023 | EXERCISE | NovoCure Ltd | 25,000 | 11.46 USD | |
| 05 Jan 2023 | SALE | NovoCure Ltd | 2,123 | 118.47 USD | |
| 05 Jan 2023 | EXERCISE | NovoCure Ltd | 187,500 | 0.00 USD | deriv |
| 05 Jan 2023 | EXERCISE | NovoCure Ltd | 25,000 | 0.00 USD | deriv |
| 05 Jul 2022 | GRANT_AWARD | NovoCure Ltd | 276 | 59.08 USD | |
| 03 Mar 2022 | GRANT_AWARD | NovoCure Ltd | 13,470 | 80.59 USD | deriv |
| 06 Jan 2022 | GRANT_AWARD | NovoCure Ltd | 31 | 63.82 USD | |
| 26 Nov 2021 | PURCHASE | NovoCure Ltd | 1,000 | 103.37 USD | first after silence |
1 purchase reported after at least 12 months of silence — most recent on 26 Nov 2021.